Radiopharmaceutical · Cytotoxic, directed at L-amino acid transporter 1 (SLC7A5) · developed by Telix Pharmaceuticals Pty
Iodine I 131 IPA is a radioconjugate of 4-iodo-L-phenylalanine labeled with iodine I 131 that targets LAT1, an amino acid transporter overexpressed in glioma cells. It crosses the blood-brain barrier and delivers cytotoxic beta radiation to malignant gliomas, with potential radiosensitizing effects. It is studied in glioblastoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05450744 | Phase 1 | Neoplastic Disease | Active not recruiting | TLX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
GlioblastomaGlioblastoma MultiformeNeoplastic Disease
Updated Oct 3, 2026. Something wrong or missing? Report it on the TLX page.
See TLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TLX catalysts and pipeline →